Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
5.59
+0.07 (1.27%)
At close: Apr 28, 2026, 4:00 PM EDT
5.60
+0.01 (0.18%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Aardvark Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Aardvark Therapeutics stock have an average target of 15.29, with a low estimate of 6.00 and a high estimate of 33. The average target predicts an increase of 173.52% from the current stock price of 5.59.
Analyst Consensus: Buy
* Price targets were last updated on Mar 24, 2026.
Analyst Ratings
The average analyst rating for Aardvark Therapeutics stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 3 | 3 |
| Buy | 3 | 5 | 5 | 5 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 10 | 10 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +61.00% | Mar 24, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $35 → $21 | Buy | Maintains | $35 → $21 | +275.67% | Mar 2, 2026 |
| BTIG | BTIG | Strong Buy Maintains $26 → $9 | Strong Buy | Maintains | $26 → $9 | +61.00% | Mar 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 2, 2026 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $29 → $7 | Buy → Hold | Downgrades | $29 → $7 | +25.22% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.05M
EPS This Year
-3.52
from -2.93
EPS Next Year
-3.61
from -3.52
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 10.8M | ||||||
| Avg | n/a | 1.1M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.63 | -1.72 | ||||||
| Avg | -3.52 | -3.61 | ||||||
| Low | -4.53 | -5.89 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.